Nasol Kids, spray 0.125 mcg/dose 10 ml

Antinoconstrictive agent – α-adrenomimetic

ATX code: R01AA04

Pharmacological properties

The drug for symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an agonist of alpha 1-adrenergic receptors (sympathomimetic) which produces a vasoconstrictor effect at the expense of stimulation of alpha 1-receptors in the nasal mucosa, reduces mucous membrane swelling and tissue hyperemia, congestion in the nasal mucosa and improves nasal airway patency. Restoration of nasopharyngeal airway patency improves the patient’s well-being and reduces the risk of possible complications caused by mucociliary congestion.

Pharmacokinetics

In topical administration, systemic absorption is low.

Indications

Symptomatic treatment: to facilitate breathing through the nose in case of colds, flu, hay fever or other allergic diseases of the upper respiratory tract, accompanied by acute rhinitis or sinusitis.

Pharmacological effect

Anticongestant – α-adrenergic agonist

ATX code: R01AA04

Pharmacological properties

A drug for the symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an alpha-1 adrenergic receptor agonist (sympathomimetic), which has a vasoconstrictor effect by stimulating alpha-1 receptors in the nasal mucosa, reduces swelling of the mucous membranes and tissue hyperemia, congestion in the nasal mucosa, and also improves the patency of the nasal airways. Restoring air patency of the nasopharynx improves the patient’s well-being and reduces the risk of possible complications caused by stagnation of mucous secretion.

Pharmacokinetics

When applied topically, systemic absorption is low.

Special instructions

In children, the systemic absorption of phenylephrine and the associated risk of side effects is higher than in adults.
The duration of use of the drug should not exceed 3 days; if difficulty in nasal breathing persists, further use of the drug should be agreed with a doctor.

Phenylephrine should not be prescribed to patients within 2 weeks of discontinuation of monoamine oxidase inhibitors as they may potentiate the adrenergic effects of sympathomimetic agents and increase the risk of cardiovascular side effects.

It is not recommended to use the same bottle by more than one person to avoid the spread of infection. When the bottle is compressed in a vertical position, the solution is released from it in the form of a spray; when the bottle is compressed in an inverted position, the solution is released drop by drop.

Impact on the ability to drive a car and use equipment

There is no data on the negative effect of the drug on the ability to drive a car or other vehicles. But if symptoms of a side effect of the drug appear, you should refrain from driving vehicles and performing actions that require concentration or psychomotor reactions.

Active ingredient

Phenylephrine

Composition

100 ml contains:

active ingredient:

phenylephrine hydrochloride 0.25 g;

excipients:

benzalkonium chloride 0.018 g,

eucalyptol (cineole) 0.040 g,

glycerol 4,000 g,

macrogol 1500 1,500 g,

sodium hydrogen phosphate dihydrate 0.226 g,

potassium dihydrogen phosphate 0.101 g,

disodium edetate dihydrate 0.020 g,

purified water 95.845 g.

Contraindications

Increased individual sensitivity to the ingredients of the drug,
diseases of the cardiovascular system (including severe atherosclerosis, angina pectoris, tachycardia)
thyroid disease (thyrotoxicosis)
diabetes mellitus
arterial hypertension
simultaneous use of MAO inhibitors (as well as 2 weeks after their withdrawal)
children under 4 years of age.

With caution in children (up to 6 years).

Side Effects

Local reactions: burning, tingling or tingling sensation in the nose.

Systemic effects: headache, dizziness, palpitations, arrhythmia, increased blood pressure, sweating, pallor, tremor, sleep disturbance.

Interaction

Monoamine oxidase inhibitors (procarbazine, selegiline), tricyclic antidepressants, maprotiline, guanedrel, guanethidine increase the pressor effect and arrhythmogenicity of phenylephrine (with systemic absorption).

Thyroid hormones during systemic absorption of phenylephrine increase (mutually) the associated risk of coronary insufficiency (especially with coronary atherosclerosis).

Overdose

May manifest as heart rhythm disturbances, increased blood pressure, and agitation.

In case of overdose, you should consult a doctor.

Treatment is symptomatic.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years

Manufacturer

Instituto de Angeli S.r.L., Italy